With the integration of the toxSYN™payload platform into the established GlycoConnect™ and HydraSpace™ technologies, Synaffix becomes a one-stop provider for technology required to rapidly translate antibodies into proprietary ADC products.  This expansion creates the possibility for essentially any company with an existing antibody to rapidly establish a highly-competitive clinical-stage ADC for its own development pipeline.

All payloads have been clinically validated with well-known efficacy and safety profiles, and were selected to address the two types of biologies that exist across ADC targets which include rapidly-dividing cancer cells as well as quiescent cells, such as cancer stem cells.

The toxSYN™ platform consists of four highly potent payloads, which offer multiple mechanisms of action and a viable path for commercialization when combined with components from the company’s GlycoConnect™ and HydraSpace™ technologies:

• SYNeamicin™ – functionalized calicheamicin (DNA damaging agent)
• SYN-38™ – functionalized SN-38 (topoisomerase 1 inhibitor)
• SYNstatin E™ – functionalized auristatin E (microtubule inhibitor)
• SYNtansine™ – functionalized maytansine (microtubule inhibitor)

These payloads are perfectly compatible with the key site-specific ADC drug formats including drug-to-antibody ratios (DAR) of 2 and 4.